QIAGEN (QGEN)
(Delayed Data from NYSE)
$46.36 USD
+0.79 (1.73%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $46.38 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$46.36 USD
+0.79 (1.73%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $46.38 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Zacks News
QIAGEN (QGEN) Extends QIAwave Product Line With New Kit
by Zacks Equity Research
QIAGEN's (QGEN) new QIAwave kits broaden its selection of environmentally friendly products and reaffirm its commitment to helping researchers advance science.
QIAGEN's (QGEN) New API Streamlines Access to BKB Data
by Zacks Equity Research
QIAGEN (QGEN) introduces API to give easier access to the QIAGEN Biomedical Knowledge Base.
Why Is Qiagen (QGEN) Down 4.8% Since Last Earnings Report?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN (QGEN) Q2 Earnings and Revenues Top, '23 View Slashed
by Zacks Equity Research
QIAGEN (QGEN) surpasses the earnings and revenue outlook in the second quarter of 2023 amid a challenging macro environment.
Qiagen (QGEN) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 2% and 0.22%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
QIAGEN (QGEN) Receives FDA Approval for AYVAKIT CDX Test
by Zacks Equity Research
QIAGEN's (QGEN) latest approval adds to its leading portfolio in precision medicine, including 12 FDA-approved companion diagnostics.
Emergent Biosolutions (EBS) Moves 6.4% Higher: Will This Strength Last?
by Zacks Equity Research
Emergent Biosolutions (EBS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
QIAGEN (QGEN) Expands Digital PCR Offering With New Pact
by Zacks Equity Research
QIAGEN (QGEN) and Niba Labs can assist companies developing cell and gene therapies to overcome significant resource limitations and adhere to stringent project deadlines.
Alkermes (ALKS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors remain optimistic about QIAGEN (QGEN) backed by the performance of the NGS portfolio and diagnostic solutions.
QGEN vs. LFCR: Which Stock Is the Better Value Option?
by Zacks Equity Research
QGEN vs. LFCR: Which Stock Is the Better Value Option?
QIAGEN's (QGEN) ForenSeq MainstAY Workflow Gets FBI Nod
by Zacks Equity Research
QIAGEN's (QGEN) ForenSeq MainstAY workflow is a cost-effective substitute for analyzing short tandem repeats with capillary electrophoresis and facilitates volume casework for sexual assault cases.
QIAGEN (QGEN) Publishes New Data on QuantiFERON TB Testing
by Zacks Equity Research
The study on QIAGEN's (QGEN) QuantiFERON-TB Gold Plus confirms the crucial role of CD8 T-cells for a broad immune assessment of TB infection.
QIAGEN's (QGEN) QCI Is Used by Danish National Genome Center
by Zacks Equity Research
QIAGEN's (QGEN) QCI Interpret offers evidence-based variant interpretation and reporting, and upholds the highest standards for data security and privacy. It also provides testing sites flexibility.
Qiagen (QGEN) Down 0.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN (QGEN) Expands Enzyme Offering to Aid Laboratory
by Zacks Equity Research
QIAGEN is a one-stop shop for all research needs, including solutions for sample preparation, automation and bioinformatics with enzyme offering expansion.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
QIAGEN (QGEN) is likely to benefit from high organic growth across its non-COVID-19 product group and portfolio advancements, reflecting a positive share price movement.
Qiagen (QGEN) Q1 Earnings Top Estimates, Operating Margin Down
by Zacks Equity Research
Amid an uncertain macroeconomic environment, Qiagen's (QGEN) first-quarter results reflect an impressive organic top line, led by strength in non-COVID-19 product groups.
Qiagen (QGEN) Q1 Earnings Beat Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 8.51% and 0.09%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Qiagen (QGEN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Qiagen (QGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Solid Biosciences Inc. (SLDB) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Solid Biosciences Inc. (SLDB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Qiagen (QGEN) Q1 Earnings Expected to Decline
by Zacks Equity Research
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QIAGEN's (QGEN) Expanded Test Menu Aids, FX Woe Lingers
by Zacks Equity Research
In terms of QIAstat-Dx, QIAGEN (QGEN) continues to witness increased demand for system placements and growing consumables usage around the world.
QIAGEN (QGEN) QIAxcel Connect Gets Red Dot Design Award
by Zacks Equity Research
QIAGEN (QGEN) QIAxcel Connect automates the analysis of the size and quality of isolated DNA and RNA.